Jubilant Pharmova Limited reported strong operational performance for FY26, with consolidated revenue rising 14% year-on-year to Rs. 8,280 crore.

The growth was supported by robust growth across Radiopharma, CDMO Sterile Injectables, Allergy Immunotherapy, CRDMO, and Generics businesses.

For Q4FY26, the company posted revenue of Rs. 2,290 crore, marking a 19% increase over the corresponding quarter last year. EBITDA for the quarter stood at Rs. 363 crore, while normalized profit after tax came in at Rs. 129 crore.

For the full year FY26, EBITDA increased 8% to Rs. 1,326 crore, while normalized PAT grew 7% to Rs. 442 crore. The board has proposed a dividend of Rs. 5 per equity share.

Shyam S Bhartia, Chairman of Jubilant Pharmova, and Hari S Bhartia, Co-Chairman and Non-Executive Director, “We delivered strong FY26 revenue growth of 14% to Rs. 8,280 crore, driven by robust momentum across businesses, particularly the rapid ramp-up of our CDMO Sterile Injectables Line 3 at Spokane, where we onboarded one of the world’s largest oncology products." 

“While EBITDA margins were impacted by temporary remediation-related disruptions at Montreal, we expect profitability to improve from H2FY27 onwards as operations stabilize and growth investments begin to scale further,” they added further.

The CDMO Sterile Injectables business emerged as one of the strongest growth drivers during the year, with revenue increasing 38% to Rs. 1,755 crore. 

In the Radiopharmaceuticals segment, revenue grew 10% to Rs. 1,178 crore despite temporary disruptions at the Montreal facility due to remediation activities following USFDA observations. 

In Allergy Immunotherapy, revenue increased 12% to Rs. 785 crore, driven by strong demand in both US and international markets. The company highlighted its position as the sole supplier of venom products in the US allergy immunotherapy market. 

The CRDMO segment continued to expand, with the Drug Discovery business posting 15% revenue growth to Rs. 654 crore. Jubilant also announced a strategic partnership with Pierre Fabre of France to expand its European footprint in biologics and antibody-drug conjugates (ADCs).